222420-33-9

Upstream product

• 3306-62-5 2-AMINOBENZENESULFONAMIDE 
• 36239-09-5 ethyl chlorocarbonylacetate 
• 105-53-3 diethyl malonate 
• 62-53-3 aniline 
• 50881-48-6 N-chlorosulfonyl-N'-phenyl-urea 
• 13338-00-6 2H-1,2,4-benzothiadiazin-3(4H)-one 1,1-dioxide 

Downstream Products

• 53971-22-5 (1,1-dioxo-1,4-dihydro-1λ⁶-benzo-[1,2,4]-thiadiazin-3-yl)acetic acid ethyl ester 
• 1071521-41-9 (1S,2R,3S,4R)-3-[[2-(1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-3-yl)-acetyl]-(4-fluorobenzyl)amino]bicyclo[2.2.1]heptane-2-carboxylic acid ethyl ester 
• 1071518-15-4 (1R,2S,7R,8S)-5-(1,1-dioxo-1,4-dihydro-1λ6-benzo[1,2,4]thiadiazin-3-yl)-3-(4-fluorobenzyl)-6-hydroxy-3-azatricyclo[6.2.1.02,7]undec-5-en-4-one 
• 303776-89-8 3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1-(3-methylbutyl)-2(1H)-quinolinone 
• 686263-53-6 1-benzyl-3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,8-naphthyridin-2(1H)-one 
• 53971-22-5 ethyl 1,1-dioxo-2H-benzo-1,2,4-thiadiazinyl-3-acettae 

Relevant academic research and scientific papers

Recyclization of 2-imino-2H-1-benzopyrans under the influence of nucleophilic reagents. 2. Reaction of 2-iminocoumarin-3-carboxamides with o-aminobenzenesulfonamide

2-Iminocoumarin-3-carboxamides recyclized into 3-(1,1-dioxo-2H-benzo-1,2,4-thiadiazinyl-3)coumarins under the influence of o-aminobenzenesulfonamide. An alternative method of synthesis is discussed. Proposed mechanisms for the recyclization are discussed.

[1,2,4]THIADIAZINE 1,1-DIOXIDE COMPOUNDS FOR LOWERING SERUM URIC ACID

The present invention describes [1,2,4]thiadiazine 1,1-dioxide compounds and pharmaceutically acceptable salts thereof, which are useful in lowering serum uric acid in a patient in need thereof comprising administering to the patient a therapeutically or

5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS

The invention is directed to 5,6-dihydro-lH-pyridin-2-one compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.

Inhibitors of HCV NS5B polymerase: Synthesis and structure-activity relationships of N-1-benzyl and N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine analogs containing substituents on the aromatic ring

A series of non-nucleoside HCV NS5B polymerase inhibitors based on the N-1-benzyl or N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine core substituted in the D-ring aromatic moiety have been prepared and evaluated. Aromatic substituents extending from position 7 of the D-ring exhibited excellent potency against both genotypes 1a and 1b.

3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase

Recently, we disclosed a new class of HCV polymerase inhibitors discovered through high-throughput screening (HTS) of the GlaxoSmithKline proprietary compound collection. This interesting class of 3-(1,1-dioxo-2H-1,2,4- benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones potently inhibits HCV polymerase enzymatic activity and inhibits the ability of the subgenomic HCV replicon to replicate in Huh-7 cells. This report will focus on the structure-activity relationships (SAR) of substituents on the quinolinone ring, culminating in the discovery of 1-(2-cyclopropylethyl)-3-(1,1-dioxo-2H-1,2,4- benzothiadiazin-3-yl)-6-fluoro-4-hydroxy-2(1H)-quinolinone (130), an inhibitor with excellent potency in biochemical and cellular assays possessing attractive molecular properties for advancement as a clinical candidate. The potential for development and safety assessment profile of compound 130 will also be discussed.

PYRIDAZINONE COMPOUNDS

The invention is directed to pyridazinone compounds and pharmaceutical compositions containing such compounds that are useful in treating infections by hepatitis C virus.